에서 실시간으로 운영 중이에요! 자세히 알아보기
BLCO 아이콘

Bausch + Lomb

16.49 USD
-0.17
1.02%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
16.49
0.00
0%
1일
-1.02%
5일
-2.02%
1개월
-3.4%
3개월
-1.9%
6개월
-0.6%
연초 이후
-0.54%
1년
10.97%
5년
-17.55%
10년
-17.55%
 

소개: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

직원 수: 13,000

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 27.8%
중립 72.2%
부정적 0%
중립
Business Wire
4일 전
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
중립
Business Wire
10일 전
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf.
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
중립
Business Wire
11일 전
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c.
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
긍정적
Zacks Investment Research
지난달
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
중립
Business Wire
지난달
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company's next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously.
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
중립
Business Wire
지난달
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting.
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
중립
Business Wire
지난달
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p.
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
긍정적
Zacks Investment Research
지난달
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
중립
Seeking Alpha
지난달
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
중립
MarketBeat
지난달
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Lightweight Charts™를 사용해 가격 차트를 구현했어요.